Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL)

Next Previous
Trial Profile

Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hepatitis B vaccine (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine (Primary) ; Hib-DTaP-poliovirus vaccine (Primary) ; Measles mumps and rubella virus vaccine (Primary) ; Measles mumps and rubella virus vaccine (Primary) ; Pneumococcal 20-valent conjugate vaccine (Primary) ; Rotavirus W179-9 vaccine (Primary) ; RSVt-vaccine-Sanofi (Primary) ; Varicella zoster virus vaccine live (Primary) ; Varicella zoster virus vaccine live (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Pharmacodynamics
  • Acronyms CORAL
  • Sponsors Sanofi Pasteur

Most Recent Events

  • 14 Jan 2025 Status changed from recruiting to active, no longer recruiting.
  • 14 Oct 2024 Planned End Date changed from 10 Mar 2026 to 30 Sep 2025.
  • 15 May 2024 Planned End Date changed from 25 Feb 2026 to 10 Mar 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top